Advanced search
Publication Cover
Cutaneous and Ocular Toxicology Volume 32, 2013 - Issue 4
Submit an article Journal homepage
179
Views
9
CrossRef citations to date
0
Altmetric
Case Reports

Cutaneous leukocytoclastic vasculitis due to erlotinib: just an adverse event or also a putative marker of drug efficacy?

Giovanni BrandiDepartment of Specialised, Experimental and Diagnostic Medicine, “L. and A. Seràgnoli” Hematology and Oncological Sciences Institute
,
Michela VenturiDepartment of Specialised, Experimental and Diagnostic Medicine, Dermatology Division, Saint Orsola-Malpighi Hospital, University of Bologna BolognaItaly
,
Emi DikaDepartment of Specialised, Experimental and Diagnostic Medicine, Dermatology Division, Saint Orsola-Malpighi Hospital, University of Bologna BolognaItalyCorrespondence[email protected]
,
Howard MaibachDepartment of Dermatology, University of California San Francisco, CAUSA
,
Annalisa PatriziDepartment of Specialised, Experimental and Diagnostic Medicine, Dermatology Division, Saint Orsola-Malpighi Hospital, University of Bologna BolognaItaly
&
Guido BiascoDepartment of Specialised, Experimental and Diagnostic Medicine, “L. and A. Seràgnoli” Hematology and Oncological Sciences Institute
Pages 336-338 | Received 19 Dec 2012, Accepted 21 Feb 2013, Published online: 27 Mar 2013

Citations (9)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Mahmoud Rezk Abdelwahed Hussein. (2016) Drug-induced skin reactions: a pathologist viewpoint. Cutaneous and Ocular Toxicology 35:1, pages 67-79.
Read now
Feng Jin, Hui Zhu, Li Kong & Jinming Yu. (2015) A spectrum of cutaneous toxicities from erlotinib may be a robust clinical marker for non-small-cell lung therapy: a case report and literature review. OncoTargets and Therapy 8, pages 943-946.
Read now

Articles from other publishers (7)

Naoyuki Senda, Tomomitsu Miyagaki, Tomonori Oka, Akira Nonogaki, Ayumi Yoshizaki, Sayaka Shibata & Shinichi Sato. (2018) Case of purpuric drug eruption probably induced by panitumumab. The Journal of Dermatology 46:6, pages e221-e222.
Crossref
Gyula Fekete & L�szl� Fekete. (2018) Cutaneous leukocytoclastic vasculitis associated with erlotinib treatment: A case report and review of the literature. Experimental and Therapeutic Medicine.
Crossref
Alexandra K. Rzepecki, Haiying Cheng & Beth N. McLellan. (2018) Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy. Journal of the American Academy of Dermatology 79:3, pages 545-555.
Crossref
Tamio Okimoto, Yukari Tsubata, Takamasa Hotta, Megumi Hamaguchi, Takae Okuno, Yohei Shiratsuki, Akari Kodama, Mika Nakao, Yoshihiro Amano, Shunichi Hamaguchi, Noriaki Kurimoto, Reiko Tobita & Takeshi Isobe. (2018) Successful rechallenge with ceritinib after leukocytoclastic vasculitis during ceritinib treatment for non-small cell lung cancer harboring the EML4-ALK fusion protein. Oncotarget 9:28, pages 20213-20218.
Crossref
Stephanie A. Holler HowardKatherine M. KrajewskiJyothi P. JagannathanMarta Braschi-AmirfarzanSree H. TirumaniAtul B. ShinagareNikhil H. Ramaiya. (2016) A New Look at Toxicity in the Era of Precision Oncology: Imaging Findings, Their Relationship With Tumor Response, and Effect on Metastasectomy. American Journal of Roentgenology 207:1, pages 4-14.
Crossref
Weiwen Chen & Yurong Qiu. (2015) Ginsenoside Rh2 Targets EGFR by Up-Regulation of miR-491 to Enhance Anti-tumor Activity in Hepatitis B Virus-Related Hepatocellular Carcinoma. Cell Biochemistry and Biophysics 72:2, pages 325-331.
Crossref
. (2013) Erlotinib. Reactions Weekly 1471:1, pages 23-23.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.